MNG792
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.389
- WNT_BETA_CATENIN_SIGNALING+0.343
- MYOGENESIS+0.304
- PANCREAS_BETA_CELLS+0.292
- KRAS_SIGNALING_DN+0.244
- UV_RESPONSE_DN+0.239
- APICAL_SURFACE+0.197
- ANDROGEN_RESPONSE+0.173
- NOTCH_SIGNALING+0.173
- HEME_METABOLISM+0.139
Top 10 suppressed
- MYC_TARGETS_V2-0.477
- OXIDATIVE_PHOSPHORYLATION-0.423
- E2F_TARGETS-0.417
- G2M_CHECKPOINT-0.378
- DNA_REPAIR-0.374
- MYC_TARGETS_V1-0.321
- UNFOLDED_PROTEIN_RESPONSE-0.292
- MTORC1_SIGNALING-0.279
- PI3K_AKT_MTOR_SIGNALING-0.247
- INTERFERON_ALPHA_RESPONSE-0.246
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7389-01A-11R-2016-07 | — | — | 0.857 |
| 2 | TCGA-56-8624-01A-11R-2403-07 | — | cohortSQ1 | 0.849 |
| 3 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.841 |
| 4 | C3L-01890 | — | cohortA2 | 0.840 |
| 5 | MNG942 | — | — | 0.838 |
| 6 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.835 |
| 7 | TCGA-AO-A12C-01A-11R-A10J-07 | — | A | 0.827 |
| 8 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.825 |
| 9 | TCGA-AO-A1KO-01A-31R-A13Q-07 | — | A | 0.824 |
| 10 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.389 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.343 | Inavolisib | — uncovered |
| MYOGENESIS | 0.304 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.292 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.244 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.239 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.197 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.173 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.173 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.139 | Temsirolimus | — uncovered |
| COAGULATION | 0.128 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.127 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.119 | Idelalisib | — uncovered |
| HYPOXIA | 0.077 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.062 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.057 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.055 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.052 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.021 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.019 | Inavolisib | — uncovered |